Initiator Pharma: Advancing in vulvodynia – Q3 review
Börskollen - Aktier, fonder och ekonominyheter
BörskollenFör dig med koll på börsen
•Kom igång: Trött på krångligt sparande? Prova spartjänsten med 4,6 / 5 i kundbetyg

Pressmeddelande

Initiator Pharma: Advancing in vulvodynia – Q3 review

MFN Publicerad: 24 Nov 08:56

DNB Carnegie has published a new commissioned research report on Initiator Pharma.

To access the full report and subscribe to future updates, visit https://access.dnbcarnegie.com/companies/1429

Information
This is a press release from DNB Carnegie. For information about DNB Carnegie commissioned research, see https://access.dnbcarnegie.com/, or contact our commissioned research team at [email protected].

About Us
DNB Carnegie is the leading and independent Nordic investment and private bank. Our operations within Corporate Finance, Securities and Research, Private Banking and Wealth Management are among the market leaders within their respective sectors. Together, they build an unbeatable combination of integrated knowledge, guiding our clients towards better business. DNB Carnegie operates in six countries and has more than 800 employees.

Läses av andra just nu

Senaste nytt